Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$124.77

10.61 (9.29%)

09:34
02/15/18
02/15
09:34
02/15/18
09:34

AnaptysBio price target raised to $162 from $115 at SunTrust

SunTrust analyst Yatin Suneja raised his price target on AnaptysBio to $162 and kept his Buy rating following his conversations with the company CEO and CFO. Suneja notes that the management commentary is consistent in expectation of a trend toward tolerance in the peanut trial and a "low double digit increase" in FEV1 in the asthma trial. The analyst states that his NPV analysis suggests that peanut indication alone could be worth $133/share, thus noting "highly favorable risk-reward into data readout".

  • 16

    Feb

  • 03

    May

ANAB AnaptysBio
$124.77

10.61 (9.29%)

01/23/18
FBCO
01/23/18
NO CHANGE
Target $135
FBCO
Outperform
AnaptysBio price target raised to $135 from $85 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for AnaptysBio to $135 saying she sees "room for upside" given the company's "many catalysts" in the next 12-18 months. The analyst lists the ANB-020 peanut allergy data in Q1, asthma data in Q2 and additional atopic dermatitis data potentially to be presented at a medical meeting in February as the key near-term catalysts. Young increased her probability of success estimate for ANB-019 on generalized pustular psoriasis from 0% to 25% ahead of getting first patient data potentially in late 2018 or early 2019 and raised her probability of success on ANB-020 in peanut allergy from 10% to 25% ahead of upcoming proof of concept data. She continues to like the pipeline story and keeps an Outperform rating on shares of AnaptysBio.
01/19/18
BARD
01/19/18
NO CHANGE
Target $144
BARD
Outperform
AnaptysBio price target raised to $144 from $81 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio to $144 from $81 as the company plans to report top-line data from its ongoing Phase 2 study of its peanut allergy drug candidate. The analyst sees expectations building for the company as the drug represent a significant upside opportunity. Bitritto-Gard reiterated her Buy rating on AnaptysBio shares.
12/18/17
RBCM
12/18/17
NO CHANGE
Target $108
RBCM
Outperform
AnaptysBio price target raised to $108 from $79 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on AnaptysBio to $108 and kept his Outperform rating, citing potential from the company's Phase 2 peanut allergy dataset in Q1 of 2018 as well as its ANB019/ANB020 antibody platform.
11/30/17
JEFF
11/30/17
NO CHANGE
Target $101
JEFF
Buy
AnaptysBio shares could rally $30 on Q1 data, says Jefferies
Jefferies analyst Biren Amin is out with his expectations for ANB020 ahead of AnaptysBio's (ANAB) Phase II data in adult severe peanut allergy expected in Q1 of 2018. The analyst thinks ANB020 could confer peanut tolerance of at least one peanut at the one month time point in about 35%-50% of ANB020 patients. Such an effect is "clearly much earlier than seen with peanut immunotherapy," Amin tells investors in a research note. The analyst thinks immune desensitization therapies, like the ones being developed by DBV Technologies (DBVT) and Aimmune (AIMT), leave "lots of room for improvement. Depending on the strength of data, AnaptysBio shares could move $20-$30 on the Q1 readout, Amin contends. He keeps a Buy rating on the shares with a $101 price target.

TODAY'S FREE FLY STORIES

DBD

Diebold

$11.07

-0.33 (-2.89%)

14:55
03/19/19
03/19
14:55
03/19/19
14:55
Options
Diebold put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$25.68

2.43 (10.45%)

, GOOG

Alphabet

$1,195.81

12.15 (1.03%)

14:54
03/19/19
03/19
14:54
03/19/19
14:54
Hot Stocks
AMD says Radeon GPUs being used for Google Stadia platform »

AMD (AMD) announced that…

AMD

AMD

$25.68

2.43 (10.45%)

GOOG

Alphabet

$1,195.81

12.15 (1.03%)

GOOGL

Alphabet Class A

$1,199.72

11.63 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SIEN

Sientra

$9.26

0.05 (0.54%)

14:51
03/19/19
03/19
14:51
03/19/19
14:51
Hot Stocks
Breaking Hot Stocks news story on Sientra »

Sientra down 6% after FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNS

WNS Holdings

$52.87

-0.14 (-0.26%)

14:50
03/19/19
03/19
14:50
03/19/19
14:50
Conference/Events
WNS Holdings management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 26

    Mar

JCOM

j2 Global

$86.67

0.76 (0.88%)

14:49
03/19/19
03/19
14:49
03/19/19
14:49
Conference/Events
j2 Global management to meet with Wedbush »

Luncheon and Dinner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FDX

FedEx

$182.02

-0.4 (-0.22%)

14:49
03/19/19
03/19
14:49
03/19/19
14:49
Options
Fedex options imply 8.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

SIEN

Sientra

$9.26

0.05 (0.54%)

14:48
03/19/19
03/19
14:48
03/19/19
14:48
Hot Stocks
FDA posts warning letter sent to Sientra »

In a letter dated March…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMASY

Inmarsat

$0.00

(0.00%)

14:46
03/19/19
03/19
14:46
03/19/19
14:46
Hot Stocks
Inmarsat confirms receipt of potential $7.21 per share offer from PE consortium »

The Board of Inmarsat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$269.61

0.15 (0.06%)

14:45
03/19/19
03/19
14:45
03/19/19
14:45
Periodicals
Tesla, Musk face dozens of suits, probes, CNBC says »

Tesla and CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

GLUU

Glu Mobile

$10.46

0.59 (5.98%)

14:45
03/19/19
03/19
14:45
03/19/19
14:45
Options
Glu Mobile call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

NOVT

Novanta

$83.83

-0.1 (-0.12%)

14:41
03/19/19
03/19
14:41
03/19/19
14:41
Conference/Events
Novanta management to meet with William Blair »

Meeting to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

  • 09

    May

AXL

American Axle

$14.66

0.305 (2.13%)

14:35
03/19/19
03/19
14:35
03/19/19
14:35
Options
American Axle put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
03/19/19
03/19
14:30
03/19/19
14:30
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

BUD

AB InBev

$83.96

1.92 (2.34%)

, MO

Altria Group

$57.06

-0.245 (-0.43%)

14:25
03/19/19
03/19
14:25
03/19/19
14:25
Periodicals
AB InBev to name former Altria CEO as Chairman, WSJ reports »

This week, Anheuser-Busch…

BUD

AB InBev

$83.96

1.92 (2.34%)

MO

Altria Group

$57.06

-0.245 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 07

    May

  • 16

    May

14:25
03/19/19
03/19
14:25
03/19/19
14:25
General news
CEA released the Economic Report of the President earlier »

CEA released the Economic…

FB

Facebook

$162.92

2.46 (1.53%)

, AMZN

Amazon.com

$1,780.97

38.97 (2.24%)

14:23
03/19/19
03/19
14:23
03/19/19
14:23
Periodicals
Instagram impinges on Amazon, others with new shopping functionality, WSJ says »

Instagram (FB), in a push…

FB

Facebook

$162.92

2.46 (1.53%)

AMZN

Amazon.com

$1,780.97

38.97 (2.24%)

SHOP

Shopify

$201.68

-4.17 (-2.03%)

WMT

Walmart

$99.96

0.29 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 26

    Mar

  • 27

    Mar

  • 04

    Apr

  • 16

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$283.22

0.76 (0.27%)

14:22
03/19/19
03/19
14:22
03/19/19
14:22
Hot Stocks
Trump says trade talks with China 'going very well' »

While walking away from a…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$283.22

0.76 (0.27%)

GOOG

Alphabet

$1,194.43

10.77 (0.91%)

GOOGL

Alphabet Class A

$1,198.48

10.39 (0.87%)

FB

Facebook

$162.98

2.52 (1.57%)

TWTR

Twitter

$31.36

0.265 (0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 23

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

TSG

The Stars Group

$17.01

0.05 (0.29%)

14:20
03/19/19
03/19
14:20
03/19/19
14:20
Options
Call buyers opening in Stars Group as shares tick higher »

Call buyers opening in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
03/19/19
03/19
14:17
03/19/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
03/19/19
03/19
14:16
03/19/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRMW

Primo Water

$15.20

-0.19 (-1.23%)

14:13
03/19/19
03/19
14:13
03/19/19
14:13
Conference/Events
Primo Water management to meet with William Blair »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

ALSN

Allison Transmission

$46.46

0.065 (0.14%)

14:13
03/19/19
03/19
14:13
03/19/19
14:13
Conference/Events
Allison Transmission management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 21

    Mar

ECL

Ecolab

$175.11

-0.03 (-0.02%)

14:12
03/19/19
03/19
14:12
03/19/19
14:12
Conference/Events
Ecolab management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 22

    Mar

  • 04

    Apr

  • 28

    May

TLGT

Teligent

$1.23

-0.065 (-5.04%)

14:08
03/19/19
03/19
14:08
03/19/19
14:08
Hot Stocks
Teligent reports FDA approval of fluocinonide topical solution USP, 0.05% »

Teligent announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMU

Immunomedics

$18.70

-0.19 (-1.01%)

14:05
03/19/19
03/19
14:05
03/19/19
14:05
Options
Immunomedics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.